PriceTargets.com logo

Calliditas Therapeutics AB (publ) - CALT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $39.25
  • Forecasted Upside: -1.88%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$40.00 As of 12/17/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CALT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Calliditas Therapeutics AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALT

Analyst Price Target is $39.25
▼ -1.88% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Calliditas Therapeutics AB (publ) in the last 3 months. The average price target is $39.25, with a high forecast of $40.00 and a low forecast of $39.00. The average price target represents a -1.88% upside from the last price of $40.00.

This chart shows the closing price for CALT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Calliditas Therapeutics AB (publ). This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/31/2024CitigroupReiterated RatingBuy ➝ Neutral$39.00
5/28/2024Lifesci CapitalDowngradeStrong-Buy ➝ Hold
5/28/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$58.00 ➝ $39.00
5/28/2024Stifel NicolausReiterated RatingBuy ➝ Hold$55.00 ➝ $40.00
5/28/2024HC WainwrightReiterated RatingBuy ➝ Neutral$39.00
5/24/2024HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $45.00
2/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
11/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
10/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$60.00 ➝ $50.00
8/18/2023GuggenheimLower TargetNeutral ➝ Neutral$21.00 ➝ $18.00
6/20/2023HC WainwrightInitiated CoverageBuy$60.00
2/28/2023GuggenheimInitiated CoverageNeutral
2/24/2023CitigroupBoost TargetBuy$76.00 ➝ $79.00
6/16/2022Kepler Capital MarketsInitiated CoverageBuy
6/2/2022Pareto SecuritiesInitiated CoverageBuy
12/20/2021HC WainwrightBoost TargetBuy$52.00 ➝ $62.00
7/7/2021SEB Equity ResearchInitiated CoverageBuy
7/7/2021SEB EquitiesInitiated CoverageBuy
2/26/2021HC WainwrightInitiated CoverageBuy$52.00
8/18/2020Ci CapitalReiterated RatingBuy$44.00
7/1/2020CitigroupInitiated CoverageBuy$36.00
6/30/2020Jefferies Financial GroupInitiated CoverageBuy$44.00
6/30/2020Stifel NicolausInitiated CoverageBuy$28.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 8 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/20/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Calliditas Therapeutics AB (publ) logo
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Read More

Today's Range

Now: $40.00
Low: $40.00
High: $40.00

50 Day Range

MA: $40.00
Low: $40.00
High: $40.00

52 Week Range

Now: $40.00
Low: $15.25
High: $43.00

Volume

N/A

Average Volume

10,339 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Calliditas Therapeutics AB (publ)?

The following equities research analysts have issued reports on Calliditas Therapeutics AB (publ) in the last twelve months: Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, and Stifel Nicolaus.
View the latest analyst ratings for CALT.

What is the current price target for Calliditas Therapeutics AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Calliditas Therapeutics AB (publ) in the last year. Their average twelve-month price target is $39.25, suggesting a possible downside of 1.9%. Stifel Nicolaus has the highest price target set, predicting CALT will reach $40.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $39.00 for Calliditas Therapeutics AB (publ) in the next year.
View the latest price targets for CALT.

What is the current consensus analyst rating for Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CALT, but not buy more shares or sell existing shares.
View the latest ratings for CALT.

What other companies compete with Calliditas Therapeutics AB (publ)?

Other companies that are similar to Calliditas Therapeutics AB (publ) include Arcellx, ADMA Biologics, Ultragenyx Pharmaceutical, Apellis Pharmaceuticals and Biohaven. Learn More about companies similar to Calliditas Therapeutics AB (publ).

How do I contact Calliditas Therapeutics AB (publ)'s investor relations team?

Calliditas Therapeutics AB (publ)'s physical mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company's listed phone number is 46-0-841-130-05 and its investor relations email address is [email protected]. The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se. Learn More about contacing Calliditas Therapeutics AB (publ) investor relations.